These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 37518874)
21. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366 [TBL] [Abstract][Full Text] [Related]
22. Axitinib: in advanced, treatment-experienced renal cell carcinoma. Yang LP; McKeage K Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347 [TBL] [Abstract][Full Text] [Related]
23. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430 [TBL] [Abstract][Full Text] [Related]
24. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843 [TBL] [Abstract][Full Text] [Related]
25. Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors. Kernt M; Thiele S; Liegl RG; Kernt B; Eibl K; Haritoglou C; Ulbig MW; Kampik A Growth Factors; 2012 Feb; 30(1):49-61. PubMed ID: 22168366 [TBL] [Abstract][Full Text] [Related]
26. Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib. Cardoso AM; Morais CM; Pena F; Marante T; Cunha PP; Jurado AS; Pedroso de Lima MC Hum Mol Genet; 2021 Apr; 30(3-4):160-171. PubMed ID: 33438013 [TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577 [TBL] [Abstract][Full Text] [Related]
28. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Rini BI; Quinn DI; Baum M; Wood LS; Tarazi J; Rosbrook B; Arruda LS; Cisar L; Roberts WG; Kim S; Motzer RJ Target Oncol; 2015 Mar; 10(1):45-53. PubMed ID: 24595903 [TBL] [Abstract][Full Text] [Related]
29. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431 [TBL] [Abstract][Full Text] [Related]
30. Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model. Merolle M; Mongiardi MP; Piras M; Levi A; Falchetti ML Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098270 [TBL] [Abstract][Full Text] [Related]
31. Axitinib for the treatment of advanced renal cell carcinoma. Akaza H; Fukuyama T Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549 [TBL] [Abstract][Full Text] [Related]
32. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. He Q; Gao J; Ge S; Wang T; Li Y; Peng Z; Li Y; Shen L J Cancer Res Clin Oncol; 2014 Sep; 140(9):1575-83. PubMed ID: 24804814 [TBL] [Abstract][Full Text] [Related]
33. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Cohen EE; Rosen LS; Vokes EE; Kies MS; Forastiere AA; Worden FP; Kane MA; Sherman E; Kim S; Bycott P; Tortorici M; Shalinsky DR; Liau KF; Cohen RB J Clin Oncol; 2008 Oct; 26(29):4708-13. PubMed ID: 18541897 [TBL] [Abstract][Full Text] [Related]
34. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets. MacLean E; Cisar L; Mehle K; Eremina D; Quigley JM J Manag Care Spec Pharm; 2016 Jun; 22(6):723-732u. PubMed ID: 27231799 [TBL] [Abstract][Full Text] [Related]
35. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H; Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330 [TBL] [Abstract][Full Text] [Related]
36. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma. Lee N; Lee JL; Lee JY Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462 [TBL] [Abstract][Full Text] [Related]
37. Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and Narvekar P; Bhatt P; Fnu G; Sutariya V Assay Drug Dev Technol; 2019; 17(4):167-177. PubMed ID: 31184962 [No Abstract] [Full Text] [Related]
38. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Bhatta SS; Wroblewski KE; Agarwal KL; Sit L; Cohen EE; Seiwert TY; Karrison T; Bakris GL; Ratain MJ; Vokes EE; Maitland ML Oncologist; 2013; 18(8):965-70. PubMed ID: 23900000 [TBL] [Abstract][Full Text] [Related]
39. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103 [TBL] [Abstract][Full Text] [Related]
40. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. Stehle F; Schulz K; Fahldieck C; Kalich J; Lichtenfels R; Riemann D; Seliger B J Biol Chem; 2013 Jun; 288(23):16334-16347. PubMed ID: 23625925 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]